Skip to main content

metronidazole

Generic: METRONIDAZOLE·Brand: FLAGYL, FLAGYL ER, FLAGYL I.V., FLAGYL I.V. RTU IN PLASTIC CONTAINER, Flagyl, LIKMEZ, Likmez, METRO I.V., METRO I.V. IN PLASTIC CONTAINER, METROCREAM, METROGEL, METROGEL-VAGINAL, METROLOTION, METROMIDOL, METRONIDAZOLE, METRONIDAZOLE HYDROCHLORIDE, METRONIDAZOLE IN PLASTIC CONTAINER, MetroCream, MetroGel, MetroLotion, NORITATE, NUVESSA, Noritate, Nuvessa, Nydamax, PROTOSTAT, Pylera, Relfy, Rosadan, SATRIC, VANDAZOLE, Vandazole

metronidazole: 6 clinical trials tracked.

metronidazole evidence translation

What we can confirm

6 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about metronidazole, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 1 study sponsors
Clinical Trials (6)

Comparing Placebo Versus Antibiotics for Acute Uncomplicated Diverticulitis

NCT07492134·Phase 2
Recruiting

Primary endpoint: Recruitment Rate

InterventionalRandomizedquadruple100 targetStarted 2026-07Completion 2028-101 site · United StatesVanderbilt University Medical Center

A Phase II Trial to Prevent Linear Growth Stunting and Malnutrition in Impoverished Children From a Low-Income Country by Treating Small Intestine Bacterial Overgrowth

NCT07451171·Phase 2
Recruiting

Primary endpoint: Conversion to Glucose Hydrogen Breath Test (GHBT) Negativity at Day 15

InterventionalRandomizedsingle60 targetStarted 2026-04Completion 2026-121 site · BangladeshUniversity of Virginia

Phase II Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

NCT06616597·Phase 2
Recruiting

Primary endpoint: Number of participants with PSA30 response

Interventionalopen58 targetStarted 2025-02Completion 2032-031 site · United StatesSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice: A PBRN Clinical Trial

NCT06131021·Phase 3
Completed

Primary endpoint: Probing Depth (PD) in millimeters

InterventionalRandomizeddouble236 enrolledStarted 2024-04Completion 2026-041 site · United StatesRutgers, The State University of New Jersey

PROMIZE: A Phase I/II Trial to Assess the Safety, Tolerability and Preliminary Anti-tumour Activity of Oral Combination Antibiotic Therapy to Modulate the Microbiome in Combination With Enzalutamide With Metastatic Castration Resistant Prostate Cancer (mCRPC).

NCT06126731·Phase 1·UTHR
Recruiting

Primary endpoint: Confirm the safety and tolerability of the combination of amoxicillin plus metronidazole (2 weeks) followed by ciprofloxacin plus vancomycin (2 weeks) along with enzalutamide in Phase I in mCRPC patients.

Interventionalopen39 targetStarted 2023-11Completion 2027-062 sites · Switzerland, United KingdomInstitute of Cancer Research, United Kingdom

Pilot Trial of Fecal Microbiota Transplantation and Re-Introduction of Anti-PD-1 Therapy in dMMR Colorectal Adenocarcinoma Anti-PD-1 Non-Responders

NCT04729322·Phase 2
Active, not recruiting

Primary endpoint: Objective response rate

Interventionalopen15 targetStarted 2021-02Completion 2027-121 site · United StatesM.D. Anderson Cancer Center